Prospective, multicenter phase II trial of ABVD chemotherapy with G-CSF in HIV-infected patients with Hodgkin's disease (HD): AIDS Clinical Trials Group (ACTG) study 149 (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Prospective, multicenter phase II trial of ABVD chemotherapy with G-CSF in HIV-infected patients with Hodgkin's disease (HD): AIDS Clinical Trials Group (ACTG) study 149 (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 16:A194 1997. Unique Identifier : AIDSLINE MED/97621066
Levine AM; Cheung T; Huang J; Testa M; USC School of Medicine, Los Angeles, CA

Abstract: Although HD is not considered an AIDS-defining diagnosis, recent studies suggest a statistically increased incidence of HD in HIV infected persons (Lyter, JCO; 13:2540 1995). No large prospective trials are yet published regarding the results of standard ABVD chemotherapy (Bonadonna, Cancer; 36:252 1975) in HIV infected pts. TREATMENT REGIMEN: On day 1 and 15, pts received Adriamycin 25 mg/m2; blenoxane 10 mg/m2; velban 6 mg/m2; DTIC 375 mg/m2, all IV, for 4-6 cycles (2 cycles beyond CR). G-CSF (5 mcg/kg) was self administered by sc injection on days 2-14 and 16-28 of each cycle. Anti-HIV therapy was begun after 2 cycles of ABVD. RESULTS: 21 evaluable HIV+ pts were enrolled, of whom 15 are currently evaluable for response. There were 16 males, and 5 females, with median age of 34 yrs (24-52). Two pts (9.5%) had history of injection drug use, the others did not. Ten were Caucasian (47.6%); 5 were African American (23.8%); and 6 were Hispanic (28.6%). Stage IV HD was present in 13 (62%), including marrow in 5, kidney in 2, and CNS, spinal cord, lung, liver and other sites in one patient each. 'B' symptoms were present in 86%. Median CD4 count at entry was 128 (2-972). AIDS prior to HD was present in 5. Tumor response data is available on 15, with CR in 9 (60%), PR in 3 (20%), and stable disease in 3. One CR pt died of relapsed HD. 17 pts developed new HIV related illness since entry on study, including 5 who had no such diagnosis at baseline. Median survival for all pts is 78 weeks. CONCLUSION: 1) ABVD is associated with relatively high CR rate in HIV+ pts 60%); (2) Median survival is short, due to intercurrent HIV related disease. (C) American Society of Clinical Oncology 1997

Keywords: *Antineoplastic Agents, Combined/THERAPEUTIC USE *Granulocyte Colony-Stimulating Factor/THERAPEUTIC USE *Hodgkin Disease/DRUG THERAPY *Lymphoma, AIDS-Related/DRUG THERAPY
971130
M97B1207

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .